Senior Vice President, C2i-genomics
Harry Hayter is a healthcare leader that is focused on driving the healthcare marketplace toward a more value-based system through the application of precision medicine/AI-based solutions . Harry currently serves as the Senior Vice President, Commercial Markets for C2i-genomics, Inc.. Prior to this position, he has served in a number of leadership positions within precision medicine/genomics focused organizations such as Grail, Inc., Tempus and Foundation Medicine. Before his transition to precision medicine, Harry spent 18 years within the Pharma/BioTech industry with companies like Takeda, United Therapeutics and Endo Pharmaceuticals in a number of different commercial focused positions. Harry serves on the Board of Directors for the National Association of Specialty Pharmacy, aiding in the understanding of how precision medicine will impact the delivery of therapeutics in many complex disease states. Outside of industry, Harry spends as much time as possible in the outdoors backcountry snowboarding, cycling and being outside.